Phase 3b open-label RCT in 274 adults with psoriasis and overweight or obesity: at week 36, 27.1% on ixekizumab plus tirzepatide vs 5.8% on ixekizumab alone achieved PASI 100 with at least 10% weight loss; gastrointestinal events were more frequent with the combination.
RCTn = 274
Lebwohl et al. Ixekizumab With or Without Tirzepatide in Adults With Psoriasis and Overweight or Obesity: A Phase 3b Randomized Clinical Trial